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Abstract
Migraine is a widespread brain disease that is classified as the second most 
disabling condition and has the third highest prevalence of all medical condi-
tions. Despite its non-emergent or life-threatening nature, migraine can progress 
to chronic type, a subform associated with significant morbidity and drug over-
use. In the management of migraine, it is important therefore to introduce early 
prophylactic treatment in order to limit migraine chronification. In this chapter, 
we will go through all the treatment options, both acute and preventive, phar-
maceutical and non-pharmaceutical following this flowchart: 1. Introduction; 2. 
General principles; 2.1 Symptomatic therapy; 2.2 Prophylactic management; 3. 
Pharmaceutical therapies; 3.1 Symptomatic; 3.1.1 Disease-specific; 3.1.2 No disease-
specific; 3.2 Prophylactic; 3.2.1 Disease-specific; 3.2.2 No disease-specific; 3.3 
Non-Pharmaceutical therapies; 3.4 Neuromodulation; 3.4.1 Invasive; 3.4.5 Non-
invasive; 3.5 Nutrient (nutraceuticals); 3.6 Dietary interventions; 3.7 Acupuncture; 
3.8 Physical therapy; 5. Patient centricity and patient education.
Keywords: therapy, pharmaceutical therapy, non-pharmaceutical therapy, 
symptomatic treatment, prophylactic treatment, devices, cognitive behavioral 
therapy, physical therapy, acupuncture, nutrient, nutraceuticals, dietary 
interventions, patient centricity, patient
1. Introduction
The last decade heralded a new era in migraine therapeutics, with the emergence 
of novel targeted therapies. Recent advances in the field of migraine research have 
resulted to newly available acute and preventive treatment options, including gepants 
(calcitonin gene-related peptide (CGRP)-receptor antagonists), anti-CGRP/R mono-
clonal antibodies (mAbs), and ditans (5-HT1F receptor agonists). Several advances 
were also achieved in non-pharmaceutical therapeutics, with the advent of devices for 
vagus nerve stimulation (VNS), external trigeminal nerve stimulation (eTNS), and 
transcranial magnetic stimulation (TMS) [1]. This chapter provides a comprehensive 
overview of available therapeutic approaches in migraine (pharmaceutical and non-
pharmaceutical), summarizing both acute and  prophylactic options.
The therapeutic management of migraine is multidisciplinary, including both 
pharmaceutical and non-pharmaceutical approaches. The choice of pharmaceutical 
treatment should be individualized, taking into consideration the characteristics of 
the migraine attack, the patients’ comorbidities, and treatment preferences [2, 3]. 
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The symptomatic migraine treatment aims to rapidly relief headache, restore func-
tion, and prevent recurrence. To date, simple analgesics, nonsteroidal anti-inflam-
matory drugs (NSAIDs), and triptans are the most widely prescribed medications 
for acute migraine [1]. Triptans (selective serotonin 5-HT1B/1D receptor agonists) 
have shown to inhibit the release of calcitonin gene-related peptide (CGRP) and 
were first approved for acute migraine therapy in the early 1990s [4]. However, 
these drugs are not efficient in all patients and might have vasoconstrictive proper-
ties that could be a contraindication [1], leaving room for new, disease-specific 
symptomatic treatments. The development of two novel classes of drugs, gepants 
(CGRP receptor antagonists) and ditans (serotonin 5-HT1F receptor agonists), for 
the symptomatic treatment of acute migraine allows management of patients that 
do not tolerate or respond to the above agents [1].
Every year about 3% of patients convert from episodic to chronic migraine (≥15 
headache days per month, of which ≥8 migraine days) [1]. It is important there-
fore to introduce early prophylactic treatment in order to limit migraine chroni-
fication. The calcitonin gene-related peptide (CGRP) antagonists were approved 
in 2018 and represent the first class of novel targeted medications specifically 
designed and approved for migraine prevention. The newly approved monoclonal 
antibodies against the ligand CGRP or its receptor (anti-CGRP/R mAbs) are 
fremanezumab, erenumab, and galcanezumab, while eptinezumab is waiting 
for approval in 2020 [5]. Ubrogepant, lasmiditan, and rimegepant are emerging 
acute migraine therapies that are also waiting to be added to the arsenal of current 
migraine management [6].
The use of non-pharmaceutical approaches is recommended as adjunct therapy 
or as alternative to the first-line pharmaceutical treatment [7, 8]. Complementary 
interventions are used to minimize the overuse of acute pain medication or adverse 
effects (AEs) and as alternative when preventive pharmaceutical therapy fails or is 
contraindicated. Non-pharmaceutical strategies suggested include approved devices 
for migraine, cognitive behavioral therapies, physical therapy, improving quality of 
sleep, acupuncture, and dietary solutions [9–11].
Overall, novel therapies signify a paradigm shift in migraine management and 
not only bring new hope to patients suffering for migraine but also change the 
clinician’s approach to the treatment of migraine [1]. While migraine therapy is 
currently undergoing tremendous development, unmet needs of patients remain, 
which, if addressed, have the potential to further enhance available treatment 
options and improve the quality of life of migraineurs. Identification of predic-
tive biomarkers for responders and nonresponders to therapies, and elucidation 
of underlying migraine pathophysiology are still lacking, and are essential 
for the development of novel therapeutic targets and individualized migraine 
prevention.
2. General principles
To date, there is no cure for migraine, but migraine can be successfully treated in 
many cases.
Therefore, education of patients is of great significance. This could be achieved 
by thoroughly explaining patients’ disorder, purpose, and means of management. 
Patient information leaflets on migraine and management are available from the 
Headache Federations (Lifting The Burden) [12]. Prior to treatment and during 
follow-up assessments, patients should be monitored and evaluated using recom-
mended assessment tools: the HALT-30 Index that assesses burden in terms of lost 
productive time, the Migraine Disability Assessment Test (MIDAS), the Headache 
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Impact Test (HIT-6), which evaluates the headache impact and severity, and the 
Headache Under-Response to Treatment Questionnaire (HURT), which evaluates 
efficacy and ensures that the optimal treatment has been reached [12–18]. A calen-
dar is recommended to be used by the patients with migraine, in order to monitor 
acute medication or overuse [12].
Regarding triggers and predisposing factors, modification of lifestyle, where 
applicable, is recommended. However, triggers are not always avoidable. Over the 
years, the significance of trigger factors in migraine has been overemphasized [2, 12].
Management of migraine in special populations (pregnant women, children, 
nonresponders, and elderly with comorbidities) should be carried out only by 
headache specialists [12].
The purpose of pharmacotherapy of primary headache is mostly to control symp-
toms in order to minimize the impact of the disorder on each individual patient’s life 
and lifestyle. For treatment to be effective, first, it is crucial that the correct diagnosis 
has been made. Then, the choice of therapy requires an individual approach, as 
each patient is unique. Severity and frequency of attacks, disability causing, other 
symptoms, time to peak, patient preferences, comorbidities, drug interactions, side 
effects, and prior therapies that failed should be all taken into consideration [2].
Acute treatment should be taken as early as possible in the headache phase to 
abort an attack. Prophylactic treatment is administered periodically in order to 
reduce the frequency and severity of migraine attacks. Often a combination of acute 
and prophylactic treatment is needed [2].
Pharmaceutical treatment for acute attacks is used almost by all patients with 
migraine. Prophylactic treatment should be recommended in nonresponders to 
acute treatment or not well-controlled patients, whose quality of life is impaired by 
migraine [12].
The following recommendations are highlighted from the Headache 
Consortiums and Federations Management principles, as the main clinical recom-
mendations that should be prioritized in pharmaceutical treatment.
2.1 Symptomatic therapy
When migraine attacks are not severe or disabling for less than 4 days per 
month, only symptomatic therapy is considered [2]. It is important to know when 
to treat a migraine attack and which therapy and route of administration are pre-
ferred, especially in patients experiencing nausea and vomiting. Generally, patients 
are advised to receive the abortive treatment as early as possible in the attack to 
reduce the intensity and duration of migraine as well as the accompanying features. 
In case of an inadequate response, it can be repeated after two hours (same or other 
treatment). There is a restriction on the duration of usage of symptomatic treat-
ment due to the probability of developing medication overuse headache (MOH). 
Thus, taking into account the criteria of ICHD-III [19], intake of symptomatic 
treatment should not exceed 10 days per month for ergotamine, triptans, or combi-
nations of drugs, or 15 days per month for NSAIDs, paracetamol, and aspirin.
Non-opioid analgesics (eg. NSAIDs, aspirin and paracetamol, or combina-
tions with caffeine) with the addition of antiemetics (if needed), are the first-line 
treatment for mild to moderate attacks. Analgesics should be administered early 
in the attack and in adequate dosage, and during the aura phase for the case of 
migraine with aura. When vomiting is present, rectal forms of analgesics and use 
of antiemetics might be suggested. It is noted that paracetamol (1 g) on its own 
has lower efficacy and it should not be considered as first-line treatment alone. 
Opioids are thought to be ineffective and potentially addictive; thus, they should be 
avoided [12].
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Triptans are recommended as first-line treatment for patients with moderate-
severe migraine attacks, or where analgesics failed. Triptans are more effective 
when administered while headache is mild, but their use during aura is con-
troversial for safety reasons. Combination therapy using triptans and NSAIDs 
should also be considered when triptans alone are not efficient to control migraine 
attacks. Subcutaneously injected sumatriptan (6 mg) should be considered when 
every other symptomatic treatment has failed, as a rescue medication. Triptans 
are associated with recurrence of migraine attack within 48 hours in up to 40% 
of patients that responded and with moderate consistency of efficacy across the 
attacks. Triptans should be avoided in uncontrolled hypertension, coronary heart 
disease, cerebrovascular disease or peripheral vascular disease, multiple risk factors 
for coronary or cerebrovascular disease. Finally, the use of triptans in the elderly 
should be with great caution due to comorbidities, preferably by headache special-
ists [12]. There are many strategies from stratified treatment to individual/tailored 
approach [20]. We suggest that a tailored approach is better as many subgroups of 
migraineurs exist and many patients exhibit adverse event in one or more therapies 
[12, 21]. All pharmaceutical symptomatic treatment is summarized in Table 1.
Table 1. 
Pharmaceutical acute treatment in migraine management.
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Table 2. 
Pharmaceutical preventive treatment in migraine management.
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2.2 Prophylactic management
Preventive treatment of migraine attacks is recommended when attacks are 
severe or frequent (more than 4 days per month) or there are contraindications, 
adverse effects, failure, or inadequate response of proper use of acute medication. 
The aim is to reduce frequency, duration, and severity of attacks and conversely 
increase the effect of acute treatment. The most important in preventive treatment 
of migraine is to know when to start the treatment and to manage and monitor 
the migraine patient, so that the disease does not switch from episodic to chronic, 
a subform associated with significant morbidity and drug overuse [22] and/or 
complicate with medication overuse headache (MOH). Today, we have both phar-
maceutical and non-pharmaceutical (devices, nutrients, etc.) treatment options in 
our arsenal.
Prophylactic pharmaceutical treatment include no disease-specific agents, such 
as beta-adrenergic blockers without partial agonism (atenolol, bisoprolol, metopro-
lol, and propranolol), calcium channel antagonists (flunarizine), antidepressants 
(amitriptyline), anticonvulsants (topiramate, sodium valproate), and botulinum 
toxin for the case of chronic migraine exclusively, and disease-specific pharma-
ceutical regiments, namely the newly introduced CGRP monoclonal antibodies 
(erenumab, fremanezumab, and galcanezumab) [12].
Drugs that appear ineffective should be discontinued only after 2–3 months at 
minimum, in order to achieve and observe efficacy. Failure of one drug does not 
predict failure of others in a different class. Tapered withdrawal may be considered 
after 6 months of good control, and should be considered no later than after 1 year 
[12]. To increase adherence, it is recommended to start with a low dose and slowly 
increase the dosage to the preferable one.
The anti-CGRP/R monoclonal antibodies have demonstrated good efficacy and 
excellent tolerability in phase II and III clinical trials with only injection site reac-
tions to be the most common treatment-related adverse events [22].
The available treatments have different efficacy and adverse events/contradic-
tions, and each option must be individualized and tailored in the patient’s profile 
and needs. All pharmaceutical prophylactic treatment is summarized in Table 2.
3. Pharmaceutical therapies
As previously stated, the pharmaceutical treatment of migraine is divided into 
symptomatic/acute (to stop the migraine crisis and alleviate the concomitant symp-
toms, e.g., nausea, vomiting) and preventive/prophylactic (to reduce the frequency, 
intensity, and severity of the attacks). Drugs from both categories are further 
divided into substances that have been designed specifically for migraine and to 
drugs that are used primarily for the treatment of other diseases (non-specific).
3.1 Symptomatic
3.1.1 Disease-specific
3.1.1.1 Ergots
Ergotamine and dihydroergotamine are the two main drugs of this category, and 
they exert their action via activating 5-HT1B/D receptors located on intracranial 
blood vessels. They also have affinity for dopamine and noradrenaline receptors 
[2]. Evidence shows that dihydroergotamine is more effective than ergotamine. 
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Nowadays, there are some preparations of ergotamine and dihydroergotamine 
alone or in combinations (usually with antiemetics or caffeine) [23, 24]. Ergots can 
also induce medication overuse headache (MOH) with very low doses and their 
use must be limited to less than 10 days per month. Contraindications are coronary 
artery disease due to the constriction of the coronal vessels [25], arterial hyperten-
sion, and cerebrovascular diseases. Due to their impact on the vascular system, 
they should not be used in combination with other vasoconstrictor drugs. Other 
contraindications include Raynaud disease, renal or hepatic failure, pregnancy, and 
lactation.
3.1.1.2 Dihydroergotamine (DHE)
It is available for oral, intravenous (IV), intramuscular (IM), subcutaneous 
(SC), and intranasal use, whereas the latter route of administration is less reli-
able and nasal irritation is a common adverse effect [26]. However, its availability 
varies across countries significantly. The combination of DHE with antiemetics 
(where the preparation is available) seems to be effective for the treatment of acute 
migraine. Intravenous formulation of DHE is very effective and well-tolerated for 
the treatment of migraine [27]. It is proposed as an acute management of chronic 
migraine in the primary care to the subgroup of patients who do not respond to 
NSAID-triptan combinations (1 mg of subcutaneous or intramuscular dihydro-
ergotamine) [26]. Nevertheless, two points must be taken into account: (i) DHE 
route of administration is mostly parenteral, and self-administration is difficult and 
takes time for the patient to learn. (ii) It is not clear if the addition of an antiemetic 
(metoclopramide) in the preparation is responsible for the efficacy of DHE 
(unknown if there is an additive action) [24]. Doses vary depending on the route of 
administration, i.e., 1 mg SC, 2 mg intranasal, and 2.5 mg per os.
3.1.1.3 Ergotamine
Ergotamine is an ergopeptine and the second migraine drug of the ergot family. 
The most common combination launched in the market is ergotamine tartare +  
caffeine. Ergotamine has been in clinical practice over 70 years, but there is no 
common ground for the use of this agent. There are many trials in the literature, 
which attempts to validate the efficacy of ergotamine. It is recommended for the 
treatment of acute headache, only in patients with prolonged attacks (>48 hours) 
or in whom headache recurrence is a substantial issue [28]. This recommendation 
is in accordance with the European Federation of Neurological Societies’ (EFNS) 
guidelines [20]. EFNS also stated that status migrainosus can be treated by dihydro-
ergotamine (low level of evidence). In many clinical trials [29–32], ergot derivatives 
showed lower efficacy than triptans and more adverse events (AE). Therefore, these 
substances should be dealt with caution [2]. Major AEs are nausea, vomiting, and 
should be avoided in patients who report these common associated symptoms of 
migraine, or later than >2 hours after the onset of migraine when the gastric stasis 
has already occurred. Other AEs are paraesthesia, and ergotism (due to long-term 
use or ergot derivatives).
3.1.1.4 Triptans
Triptans are 5-HT1B/1D receptor agonists and very effective for the acute 
management of migraine. They are specific to treat migraine as they act at the 
pathophysiology of migraine, inducing vasoconstriction, inhibiting pain pathways, 
and reducing the input to the trigeminal nucleus caudalis. There are many available 
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triptans, i.e., sumatriptan, naratriptan, zolmitriptan, rizatriptan, almotriptan, ele-
triptan, and frovatriptan. With the exception of sumatriptan (oral, subcutaneous, 
and intranasal) and zolmitriptan (oral and intranasal), the other triptans are for 
oral use only. Generally, triptans are recommended for moderate to severe attacks 
and there is good evidence (level A) that combining a NSAID with a triptan will 
prevent from migraine recurrence [2, 12, 20, 21]. The choice of triptan is and should 
be individualized. Triptans have different pharmacokinetic and pharmacodynamic 
profile. Subcutaneous sumatriptan (6 mg) is more effective than oral sumatriptan 
and is preferred when associated symptoms, such as nausea and vomiting, occur. 
Intranasal spray has fewer side effects than intramuscular sumatriptan (discomfort, 
nasal irritation, and unpleasant taste). Comparative studies show that eletriptan 
has the highest efficacy with short-term and sustained effect. The above conclusion 
is consistent in many studies. Rizatriptan and zolmitriptan are thought to come in 
second and third place, respectively, in terms of efficacy, although further analysis 
shows that sumatriptan, rizatriptan, almotriptan, and zolmitriptan are very similar 
regarding clinical outcome. Naratriptan and frovatriptan have less but longer 
efficacy than sumatriptan and are relatively safer than other triptans. Naratriptan, 
frovatriptan, and almotriptan are also preferred for symptomatic treatment in 
patients that migraine attack recurs after successful treatment (pain free and most 
bothersome symptom free in 2 hours posttreatment) [2, 12, 20, 21, 24, 33–36]. 
Triptans can be given in combination with NSAIDs and the effect is considered 
to be additive. The most common and well-documented combination is that of 
sumatriptan with naproxen and is the one indicated for migraine attacks that do not 
respond to oral high efficacy triptans (e.g., eletriptan 40 or 80 mg, or rizatriptan 
10 mg) [21]. Another combination that showed effectiveness in acute treatment is 
frovatriptan with dexketoprofen. Generally, triptans are safe and effective. Due to 
the vasoconstrictive action, triptan should be avoided to migraineurs with uncon-
trolled arterial hypertension, cardiovascular and/or cerebrovascular disease, and 
peripheral vascular disease. Systematical reviews and cohort studies showed that 
there is not any correlation between the use of triptans and higher cardiovascular 
risk, however [37, 38]. Nonetheless, the use of triptans is not recommended in high-
risk patients. Finally, as with ergots, the use of triptans should be limited to 10 days 
per month to avoid medication overuse headache [2, 19–21].
3.1.1.5 Ditans
Ditans are a relatively new and different class of specific acute migraine manage-
ment. The first and only approved by the Food and Drug Administration (FDA) 
until now is lasmiditan, a selective 5-HT1F receptor agonist, which shows minimal 
to zero vasoconstrictor activity in contrast to triptans. It is a suitable candidate for 
migraineurs where triptans are contraindicated or not well tolerated. Lasmiditan 
is given orally (starting dose of 50 mg and subsequently increase up to 200 mg 
if there is no benefit). Because lasmiditan penetrates the blood-brain barrier; it 
presents common AEs from the central nervous system (CNS, dizziness, somno-
lence, fatigue, and nausea) that restricts its use to those who drive or operate heavy 
machinery [39–42].
3.1.1.6 Gepants
The study of CGRP and its implication to the pathophysiology of migraine has 
led to discovery of a new class of drugs that are CGRP receptor antagonists. Gepants 
are suitable for treatment of acute migraine in patients who do not tolerate the trip-
tans or when triptans are contraindicated. The first attempts for the manufacture of 
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these type of drugs led to a dead end, as many of the trials were terminated due to 
hepatotoxicity. Now, we have two gepants that received FDA approval, ubrogepant 
(2019) and rimegepant (2020) for the treatment of acute migraine in adult patients. 
However, more clinical trials and real-world evidence are needed to prove their 
efficacy and tolerability [43].
3.1.2 No disease-specific
3.1.2.1 Nonsteroidal anti-inflammatory drugs
The most well-studied drugs of this category include acetylsalicylic acid (ASA) 
(aspirin 900–1000 mg), ibuprofen (200–800 mg), naproxen (275–825 mg), diclof-
enac (50–100 mg), tolfenamic acid (200 mg), and dexketoprofen (50 mg) [44–51]. 
The difference in dosage depends on the available formulation for each country 
and the proposed guidelines of each Headache Society [2, 12, 20, 21, 24]. The use 
of NSAID should be as soon as possible to achieve maximal effect and to preempt 
the gastric stasis. If the migraineur does experiences nausea or vomiting, parenteral 
formulations (suppository, intramuscular, and intravenous) of the above drugs 
should be given with combination of a prokinetic (see below Prokinetics) [12]. 
For moderate to severe attacks, combinations of NSAID with triptans are recom-
mended. All NSAIDs have more or less (depends on the COX-2 selectivity) the same 
adverse events including GI bleeds, peptic ulceration, hemorrhagic cerebrovascular 
accidents, and renal impairment. They should not be given in patients with uncon-
trolled hypertension or history of peptic ulcer. In case of peptic ulcer, they can be 
prescribed for a small period of time together with protein pump inhibitors (PPIs).
3.1.2.2 Acetaminophen
Acetaminophen (paracetamol 1000 mg) is a NSAID with different mecha-
nism of action. It is effective in some patients although it has weaker recommen-
dation than NSAIDs for the management of acute headache [12]. On the other 
hand, the combination of paracetamol with ASA and caffeine is more effective 
than single drugs and is recommended for the treatment of mild to moderate 
severity attacks [20, 21, 52–54].
3.1.2.3 Antiemetics/Prokinetics
Many antiemetics (metoclopramide, domperidone, chlorpromazine, prochlor-
perazine, droperidol, ondansetron, and granisetron) have been studied for the 
treatment of acute migraine, both as monotherapy as well as adjuvants. The main 
action as prokinetics is via their dopamine receptor antagonism. Many of them 
show anti-migrainous action. With the exception of metoclopramide and domperi-
done, the other antiemetics have a higher risk of QT prolongation and higher rates 
of acute dystonic reactions, akathisia (extrapyramidal action) and mild sedation, 
and besides their efficacy (even some of them over triptans) [55–59], they are not 
recommended for the treatment of migraine. On the other hand, metoclopramide 
is a mild analgesic when given orally and more efficient when given intravenously. 
Despite monotherapy with antiemetics is not recommended, adjuvant therapy [45], 
especially when associative symptoms like nausea or vomiting are present, or latter 
in the course of migraine (gastric stasis has already occurred), is strongly sug-
gested. The usual dose is for domperidone 10 mg (supportive evidence of efficacy 
is for 20 mg) up to three times per day or 30 mg (by suppository up to twice per 
day) and for metoclopramide 10 mg (up to three times per day). Metoclopramide 
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20 mg is recommended for adults and adolescents, whereas domperidone 10 mg for 
children due to the possible side effects (dyskinesia, akathisia) [12, 20].
3.1.2.4 Other drugs
Other drugs with low level of evidence that are found to be effective in the 
acute treatment of migraine attacks are intravenous valproate (dose up to 800 mg) 
[60–62], adjunctive therapy with parenteral dexamethasone (intramuscular or 
intravenous) for treatment of acute migraine and status migrainosus [20, 21, 63, 
64], and a combination of paracetamol with intravenous tramadol [65].
3.2 Prophylactic medications
3.2.1 Disease-specific
3.2.1.1  Anti-calcitonin-gene-related peptide/receptor monoclonal antibodies  
(anti-CGRP/R mAbs)
All four anti-CGRP/R mAbs share several pharmacokinetic advantages over 
small anti-CGRP/R molecules (e.g., greater target specificity and prolonged half-
life, making them suitable for monthly administration to prevent migraine). Three 
of these macromolecules target the CGRP ligand (fremanezumab, galcanezumab, 
and eptinezumab), while a fourth (erenumab) targets the CGRP receptor [66–68]. 
They require parenteral administration and have a preferential peripheral site of 
action, since only 0.1–0.5% of the mAb cross the blood–brain barrier due to their 
large size (molecular weight around 150 kDa) [66, 69–72]. All four mAbs have 
shown particular effectiveness for the prevention of both episodic and chronic 
migraine [71, 72]. Besides the initial skepticism regarding their safety and their 
potential cardiovascular effect (due to preclinical data that came from studying 
and blocking CGRP,66) and liver toxicity that emerged after the initial failure of 
gepants, no safety flags occurred during the large program of their development 
and all four anti-CGRP/R mAbs have shown similar tolerability and safety in 
Phase II and III trials. The most common AEs, which were reported during clinical 
trials, are injection site pain, erythema, respiratory infection, nasopharyngitis, 
sinusitis, influenza, urinary infection, fatigue, nausea, vomiting, joint pain, back 
pain, headache, abdominal pain, dysmenorrhea, and dry mouth. Real-world 
evidence revealed constipation as one of the common adverse effects (not in clini-
cal reporting). Anti-CGRP/R mAbs should be avoided in pregnant and nursing 
women, as well as in patients with psychiatric, pulmonary, and cardiovascular 
medical history, until more data are available. Regarding their efficacy, there is 
not much evidence or head-to-head clinical trials to support the superiority of 
one drug against the other. Due to their mechanism of action, pharmacokinetics, 
clinical effect, and cost, Headache societies have formulated practical guides on 
the proper use of anti-CGRP/R mAbs [5, 12, 21].
3.2.1.2 Erenumab
Erenumab is the first drug of the anti-CGRP/R category and the only until now 
that prevents native CGRP ligand binding to the CGRP receptor. It is an IgG2 anti-
body and the only fully human anti-CGRP/R mAb. At 70 mg, the estimated elimi-
nation half-life of erenumab is 21 days, supporting monthly subcutaneous dosing 
and, thus, betterment in patient compliance [73–75]. It is recommended for both 
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episodic and chronic migraine, as well as the treatment of MOH [76]. There are two 
formulations of erenumab (70 and 140 mg) with almost similar efficacy, and there 
is a suggestion of starting with the lower dose and increase if there is little efficacy 
[77]. A review of 3 randomized trials and their extensions suggested that erenumab 
140 mg monthly might be preferred over the 70 mg monthly dose in patients with 
EM or CM and prior preventive treatment failures (>2) [77]. It is administered sub-
cutaneously (SC) once per month, thus achieving better adherence among migraine 
patients compared to oral daily medications.
3.2.1.3 Fremanezumab
Fremanezumab is a fully humanized IgG2 mAb that potently and selectively 
binds to both α and β isoforms of CGRP [78]. It is effective for the prevention of 
episodic and chronic migraine. It is administered SC and has one formulation of 
225 mg, which can be administered either once per month, or three consecutive 
doses (total of 675 mg) every 3 months. Both dosage options have shown similar 
efficacy and adverse events [79].
3.2.1.4 Galcanezumab
Galcanezumab is a humanized IgG4 mAb with a long half-life (~28 days) 
that binds to both α- and β-CGRP isoforms with approximately equal affinity 
[80]. Again, several trials have proven its efficacy for the preventive treatment of 
migraine [81–83]. As the other two aforementioned mAbs, galcanezumab is subcu-
taneously administered. The suggested starting dose is 240 mg (2 consecutive doses 
of 120 mg formulation) as a starting dose and then 120 mg subcutaneously every 
month [84].
3.2.1.5 Eptinezumab
Eptinezumab is the last anti-CGRP/R mAb discovered till now. It is a humanized 
IgG1 antibody that potently and selectively binds to both α and β forms of human 
CGRP [85]. The plasma half-life of eptinezumab after an intravenous infusion of 
1000 mg is 31 days. There are two clinical trials (PROMISE-1 and PROMISE-2) 
that support its efficacy in episodic and chronic migraine prevention [86, 87]. 
Eptinezumab is the only intravenously anti-CGRP/R mAb and the recommended 
dose is 100 mg over 30 minutes every 3 months. It is not yet approved by the FDA or 
EMA (under development).
3.2.2 No disease-specific
Several drug classes, originally developed for other diseases (e.g., epilepsy, 
hypertension), have shown efficacy for the preventive treatment of migraine. 
Repurposed drugs may lack the disease-specific mechanism of action and have 
several adverse effects and contraindication, but show comparable efficacy to 
CGRP mAbs and are less expensive. As with the use of disease-specific treatments, 
when using nonspecific drugs, our main goal is individualizing our choice, taking 
into account the clinical characteristics, medical history, and comorbidities of the 
patient (e.g., sex, weight, anxiety/depression, hypertension, endocrinological dis-
orders, pregnancy, etc.). The main categories are anticonvulsants, antihypertensive 
and antidepressant drugs, and other agents (e.g., onabotulinumtoxinA, butterbur, 
coenzyme Q10, NSAIDs, and others).
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3.2.2.1 Anticonvulsants
3.2.2.1.1 Topiramate
Topiramate is one of the most studied drugs for the prevention of migraine, 
with several clinical studies, systematical reviews, and meta-analysis, showing 
its efficacy for both episodic and (fewer evidence) chronic migraine [26, 88–93]. 
Usual dosage ranges between 25 and 100 mg daily (in two divided doses) and there 
is suggestion, with the risk of more adverse events, of increasing the total dose 
up to 200 mg daily when the effect is suboptimal [2, 12, 20, 21, 26]. Main AEs of 
topiramate are paresthesia/numbness (results in intolerance), fatigue, anorexia/
weight loss, memory and concentration difficulties, and renal calculi (uncommon 
but serious adverse effect). It is contraindicated in pregnant women as it increases 
the risk of facial clefts and lowers birth weight. Due to the weight loss, topiramate is 
recommended to obese migraine patients [89, 90, 94].
3.2.2.1.2 Valproate
Whereas valproate is indicated for the preventive treatment of episodic migraine, its 
side effects (nausea, somnolence, dizziness, weight gain, and hair loss) and the contra-
indication to women in childbearing age and pregnancy (teratogenic) have limited its 
use. Usual doses range between 500 and 1800 mg per day and there is limited evidence 
of intravenous administration of valproate in status migrainosus [2, 12, 20, 21, 95].
3.2.2.2 Other anticonvulsants
Other anticonvulsants, such as gabapentin, have not proven their efficacy for 
prevention of episodic migraine and therefore are not recommended [96, 97] .
3.2.2.2.1 Antihypertensive
The two major categories of antihypertensive drugs that show migraine preven-
tive effect are beta-blockers and calcium channel blockers. Most of the evidence 
emerged from studies regarding hypertension reported fewer headaches in the 
intervention group vs. the placebo group [98].
3.2.2.3 Beta-blockers
Beta-blockers that are available in almost every country and are recommended 
from almost all Headache Societies for the preventive treatment of episodic 
migraine are metoprolol (50–200 mg daily) and propranolol (40–240 mg daily). 
Other beta-blockers with fewer studies are atenolol (25–100 mg daily), nadolol 
(20–240 mg daily), timolol (10–30 mg daily), and bisoprolol (5–10 mg daily). Beta-
blockers are recommended in hypertensive patients who are under 60 years old or 
nonsmokers [94, 99, 100]. Due to their mechanism of action and their dosage that 
is proven to be efficacious for migraine prevention, are not well tolerated and are 
contraindicated in patients with bradycardia, low blood pressure, cardiac conduc-
tion blocks, asthma, depression, and Raynaud phenomenon [2, 12, 20, 21, 101].
3.2.2.4 Calcium channel blockers
The only drug of this category with good level of evidence is flunarizine, a non-
specific calcium channel blocker, with calmodulin binding properties and histamine 
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H1 blocking activity. Recommended dose ranges between 5 and 10 mg daily and is 
prescribed to hypertensive patients older than 60 or smokers, as well as to patients with 
Raynaud syndrome. The most common AEs are weight gain, daytime sedation, stomach 
complaints, and dry mouth, and while there are reports of depression and extrapyra-
midal symptoms, there is no confirmation [102]. Verapamil is another calcium channel 
blocker with migraine preventive properties, but it has conflicting supporting data and 
many Headache Societies do not accept its use for episodic migraine [2, 12, 20, 21, 103].
3.2.3  Angiotensin receptor blockers (ARBs)/angiotensin converting enzyme (ACE) 
inhibitors
There is also data supporting the use of ACE inhibitors and ARBs as preventive 
migraine treatments. Candesartan, a specific ARB, has shown positive results in small-
scale crossover studies and is used for migraine prophylaxis (16–32 mg) [104, 105]. 
The most common AEs include back pain, dizziness, flu-like symptoms, sore throat, 
and nasal congestion. Similarly, a small-scale double-blind cross-over study, found 
lisinopril (ACE inhibitor) to be effective in episodic migraine [106]. The above data are 
not universally approved [2, 12, 20, 21].
3.2.3.1 Antidepressants
Antidepressants are recommended as a second-line drugs with level B documenta-
tion [20]. The two drugs of this category are amitriptyline and venlafaxine. Among the 
two amitriptyline, a tricyclic antidepressant has been studied the most [103]. The usual 
dose ranges between 10 and 150 mg. Its sedative properties have limited its use and it 
is suggested only at bedtime and especially to those who suffer from insomnia. It also 
has a place as a second choice drug for chronic migraine [26]. Except sedation, amitrip-
tyline’s AEs include dry mouth, urinary retention, constipation, weight gain, blurred 
vision, and tachycardia. Venlafaxine, a serotonin-norepinephrine reuptake inhibitor, 
has a weaker recommendation as migraine prophylaxis and is preferred to those who 
suffer from depression and/or anxiety and those who have also tension-type headaches 
(TTH). The usual dose ranges between 37.5 and 150 mg daily [2, 12, 20, 21, 94].
3.2.4 Other drugs
3.2.4.1 OnabotulinumtoxinA
Whereas many randomized trials did not prove onabotulinumtoxinA’s efficacy for 
treating episodic migraine (EM) and it is not recommended [107–109], data extracted 
from chronic migraine (CM) trials recommend onabotulinumtoxinA as an effective 
and well-tolerated treatment. OnabotulinumtoxinA has a good level of documentation 
(Level A), and there is specific protocol regarding its use (PREEMPT protocol), moni-
toring of the patients, and evaluating their response. It should be administered accord-
ing to the PREEMPT injection protocol, i.e., injecting 155 U–195 U to 31–39 sites every 
12 weeks. The most common reported AEs are neck pain, muscular weakness, eyelid 
ptosis, and injection-site pain, and the sub-analysis of the PREEMPT studies found that 
adverse events decreased over time [26, 110–112]. Its use in CM with MOH is debatable 
after a recent trial that showed no superiority against acute withdrawal alone [113].
3.3 Non-pharmaceutical therapies
Like the pharmaceutical, the non-pharmaceutical treatments—neuromodula-
tion devices in particular—gain even more ground in the treatment of migraine. 
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A set of variables arrange this alternative so far, therapeutic approach. First, the 
pathophysiology of migraine refers to a multidisciplinary spectrum of mechanisms; 
second, the disease is among the most disabling medical conditions requiring appli-
cation of all available treatment options; third, the existing medicinal selections 
(symptomatic or preventative) are related with poor adherence due to safety and 
poor response rates ; and finally, there is an international movement encouraging 
non-pharmaceutical interventions in medicine, including the community mitiga-
tion strategies. Patients’ preferences rate the non-pharmaceutical interventions 
for migraine highly [3]. All these factors create large space for non-pharmaceutical 
treatment options in migraine, which can be used alone or as adjunct therapy to 
pharmacological agents minimizing unnecessary drug exposure. There is good 
evidence for neuromodulation and biobehavioral therapies, including cognitive 
behavioral therapy (CBT), biofeedback, and relaxation training. Less evidence sug-
gests physical therapy, sleep management, acupuncture, and dietary modifications.
3.4 Neuromodulation
Neuromodulation approaches for migraine treatment includes invasive and 
noninvasive ones. Both procedures act by stimulating the nervous system centrally 
or peripherally, leading to pain relief, either acutely or preventively. They are 
constantly gaining space in the treatment of migraine and are addressed either to 
refractory patients or to patients who do not want medical treatment. All neuro-
modulation devices are summarized in Table 3.
3.4.1 Invasive
There are three invasive neurostimulation methods investigated for migraine 
and available, yet in very limited use because of the high cost of the device, the sur-
gical implementation needed, and the lack of good evidence of efficacy. In addition, 
their accessibility and reimbursement vary by country significantly. Thus, they are 
recommended for patients with refractory forms of CM only. The most common 
AEs include migration of the leads, infection, and paraesthesias [7].
3.4.2 Invasive occipital nerve stimulation (iONS)
Invasive occipital nerve stimulation (iONS) has been used to treat refractory CM 
cases. The exact mechanism of the neuromodulation effect in CNS remains unclear. 
From three randomized, sham-controlled studies [114–116], only one showed a 
significant improvement of migraines in the treated group comparing to sham 
group or the medication treated group [115]. Electrodes must be implanted subcu-
taneously above the great occipital nerve (GON), which present great anatomical 
variability among individuals [117]. The leads are implanted bilaterally, while a 
small generator is implanted subaxillary. The AEs include lead migration, paraes-
thesias, infections, and battery depletion, but safety data look better than the other 
invasive procedures [116].
3.4.3 Vagal nerve stimulation (VNS)
Vagal nerve stimulation (VNS) is already applied in patients with refractory 
epilepsy. The stimulation of vagal afferents decreases the activity of the nociceptive 
neurons of the spinothalamic and spinoreticular tract, which, in their turn, inhibit 
the nociceptive transmission in spinal and trigeminal nucleus complex, leading to 
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cephalic pain control. There is data from case series with refractory CM only show-
ing that patients with implanted VNS (iVNS) reached more than 50% reduction in 
headache frequency and severity [118, 119]. The scarce clinical experience in this 
field make iVNS not a common treatment option, for the time being, since it is an 
invasive procedure with adverse effects (infection, muscle cramps, local pain, and 
battery depletion), though the clinical experience in the field of epilepsy shows to 
be safe.
3.4.4 High cervical spinal cord stimulation
This invasive procedure trialed in open label studies in patients suffering from 
CM and showed a significant reduction in headache frequency and intensity in 
treated patients, but further investigation is required [120, 121].
Table 3. 
Neuromodulation in migraine management.
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3.4.5 Noninvasive
Noninvasive neuromodulation devices provide a safe and well-tolerated thera-
peutical option in symptomatic and prophylactic treatment of migraine alone or in 
combination with pharmaceutical treatment. Their evidence of efficacy is moderate 
to good and almost equivalent to that of drug treatments, while their safety profile 
may outperform them. There are accessibility, reimbursement, and price issues, 
however.
3.4.6 Supraorbital nerve stimulation
This is a peripheral noninvasive nerve stimulation or an external trigeminal 
nerve stimulation device which initiates transcutaneously a mild electric cur-
rent via leads that are placed on the forehead, stimulating supraorbital and 
supratrochlear nerves. There is evidence of dysregulated central and peripheral 
pathways in migraine and evidence that external trigeminal nerve stimulation 
may normalize function of these pathways [122]. Sham-controlled studies showed 
that 1-hour stimulation with this device reliefs headache pain during a migraine 
attack significantly [123], while daily 20-minute treatment decreases the monthly 
migraine days in patients suffering from EM [124]. The device is FDA approved 
and CE marked as preventive and acute therapy in migraine. Only mild AES are 
reported and despite some concerns related to the methodology followed in the 
preventive trial, its efficacy seems comparable to pharmaceutical preventive 
treatments [122, 125].
3.4.7 Transcranial magnetic stimulation (TMS)
TMS is a well-established and safe procedure already applied in other neurologi-
cal diseases, modulating the excitability of cortical neurons dependently on the 
frequency of the stimulus. Thus, only the single-pulse stimulation (sTMS) and the 
repetitive-pulse stimulation (rTMS) are used to treat migraine.
sTMS is proved to inhibit both mechanical and chemically-induced cortical 
spreading depression in animals [126]. In addition, sTMS attenuates the evoked 
firing rate of third-order thalamocortical projection neurons, indicating the 
probable neuromodulatory effect in migraine [126]. Overall, sTMS interrupts 
the brain hyperactivity associated with migraine. sTMS devices are portable and 
patient-controlled and are applied over the occipital cortex in patients with either 
migraine with aura (MwA) or migraine without aura (MwoA) for acute or preven-
tive treatment. One sham-controlled study showed that sTMS caused higher rates in 
2-hour pain relief posttreatment than the sham group in patients with MwA [127]. 
Open-label studies have shown an efficacy either in acute or preventive treatment 
in MwA or MwoA [128–131]. The most common AEs recorded in the trials were 
lightheadedness (3.7%), tingling (3.2%), and tinnitus (3.2%) [131]. The device is 
FDA approved for acute and preventive treatment of migraine for people aged more 
than 12 years.
rTMS and especially high frequency rTMS seem to have a positive effect in the 
prevention of both EM and CM. Treatment with rTMS caused a significant decrease 
of monthly headache days over sham-treated patients, for both cases of CM [132] 
and EM [133], but another sham-controlled study did not confirm the results in 
CM, probably because of a large effect size [134]. Overall, the majority of rTMS 
studies reported reductions in headache frequency, duration, intensity, abortive 
medication use, depression, and functional impairment, with no significant adverse 
events [135]. Further investigation is needed, however.
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3.4.8 Noninvasive vagus nerve stimulation (nVNS)
As in iNVS, the nVNS results in an ascending antinociceptive on trigeminal 
nucleus complex. In addition, nVNS inhibits cortical spreading depression in 
rats [136]. In migraineurs, the device is applied on the neck, and it produces an 
electrical stimulus of adjustable intensity, and therefore, stimulates transcutane-
ously the cervical part of vagus nerve. The evidence of efficacy in symptomatic 
treatment of migraine is good [8]. One sham-controlled, class 1 study has showed 
its efficacy in acute treatment of migraine [137], whereas its efficacy in migraine 
prevention remains debatable [138–140]. It is used in acute treatment of migraine 
with consisted results similar to the use of NSAIDs or triptans [141]. In a small-size 
open-label study, nVNS showed promising results as mini-prophylactic treatment 
of the menstrual migraine [142]. Reported AEs are neck twitching, change in voice, 
and redness at the site of stimulation. It is generally well tolerated by the patients, 
however. The portable nVNS device has received FDA approval and is CE marketed 
for the symptomatic treatment of migraine.
3.4.9 Remote electrical neuromodulation (REN)
Not only cranial nerves but also peripheral somatic nerve stimulation may also 
modulate cephalic pain processing, via descending endogenous analgesic mecha-
nisms (conditioned pain modulation). There is evidence that the stimulation of 
upper arm peripheral nerves (median and musculocutaneous) controls cephalic 
pain [143]. A noninvasive, portable, and wireless device, applied on the lateral 
upper arm between the bellies of deltoid and triceps muscles, delivers electrical 
stimuli that alleviate migraine pain [144]. The device has been tested for acute 
migraine treatment in one randomized, sham-controlled study showing superior-
ity over sham stimulation in achieving pain relief and freedom and relief of most 
bothering symptoms without significant AEs [145]. Notably, the treatment efficacy 
is comparable with this of the current use pharmaceutical ones [146]. Its use is 
contraindicated to patients with other active implantable medical devices and it is 
FDA approved for the symptomatic treatment of migraine.
3.4.10 Transcranial direct current stimulation (tDCS)
There is some evidence suggesting that tDCS modulates cortical hyperexcitabil-
ity and therefore it serves as a preventive treatment for CM and EM. The small-size, 
sham-controlled studies based on both rationales of anodal stimulation (excitatory) 
and cathodal (inhibitory) on visual cortex mostly have shown positive effect—with 
limitations—on reduction in monthly migraine days, headache frequency, pain 
duration, and severity. Contradictions include previous stroke or epilepsy and 
comorbidity with psychiatric disorders, among others. This procedure is under 
investigation currently [147–150].
3.4.11 Percutaneous mastoid stimulation
There is evidence suggesting that the stimulation of fastigial nucleus displays 
neuroprotective, in particular the stimulation of fastigial nucleus elicits long-
lasting suppression of periinfarction depolarizing waves and protect rats against 
cerebral ischemia [151]. Because cortical spreading depression shares characteristics 
with periinfarction depolarizing waves, it was speculated that this stimulation of 
this nucleus may be useful in migraine prevention [152]. The new device for this 
purpose has electrodes that are placed on the bilateral ear mastoid over the skin. 
Migraine
18
After few open label studies, one sham-controlled showed a significant reduction 
in migraine days and response rate vs. sham group in patients suffering from EM, 
without AEs [152]. The device is under development and further studies are needed.
3.5 Nutrient (nutraceuticals)
Nutraceuticals have been defined as, “a food (or part of a food) that provide 
medical or health benefits, including the prevention and/or treatment of a disease” 
[153]. There is an increasingly and demanding use of them by sufferers of chronic 
diseases including migraine [154], for which there is evidence supporting cerebral 
energy deficiency [155]. Nutraceuticals may cover this metabolic gap in brain, but 
the equality of data is low to moderate, however.
3.5.1 Riboflavin
Riboflavin (vitamin B2) is an essential component and precursor of riboflavin 
5-phosphate, and modulates the electron transport chain, contributing in energy 
production in mitochondria. There is evidence indicating that oxygen metabolism 
is impaired in migraineurs’ mitochondria resulting in energy insufficiency [155]. 
Results from placebo-controlled studies showed efficacy in reducing the frequency 
of headache days in adult migraineurs [156], but not children [157], or when 
administered as component in compliment [158]. According to available evidence, 
riboflavin could be suggested as preventive treatment in adults with EM in a daily 
dose of 400 mg [20, 159, 160].
3.5.2 Coenzyme Q10
Coenzyme Q10 has a similar action with riboflavin. In placebo-controlled 
studies, CoQ10 reduced the monthly headache days in adults with EM [161] but 
its efficacy in children and adolescents remains unclear [115]. There is Level C 
recommendation for its use as prophylactic treatment in EM [20, 160], and strong 
recommendation from the Canadian Headache Society (CHS) [159] in a dosage of 
100 mg TID.
3.5.3 Magnesium
Magnesium deficiency may increase migraine susceptibility. Oral magnesium 
has been studied in migraine prophylaxis largely [162], as the intravenous MgSO4 
for the symptomatic treatment of migraine [163]. Oral magnesium is suggested 
for migraine prophylaxis with level B or C of evidence [20, 160], in a daily dose of 
600 mg. A later meta-analysis downgraded the level of evidence, however [162]. 
Adverse events with magnesium are soft stool, diarrhea, and flushing. For the 
symptomatic treatment of migraine, intravenous MgSO4 has failed to show ben-
eficial effect in terms of reduction of pain and rescue medications, while several 
adverse effects reported questioning the clinical relevance of this symptomatic 
treatment [163].
3.5.4 Petasites hybridus or Butterbur
Petasites is a herbal extract, with moderate to good evidence of efficacy in 
migraine prevention [164, 165]. However, there are safety issues related with liver 
toxicity [166]. Yet, it is recommended as a second-choice treatment for the preven-
tion of migraine [20, 167].
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3.5.5 Tanacetum parthenium (Feverfew)
Feverfew is a medicinal plant that has been investigated for the migraine pro-
phylaxis with controversial results. A recent review presents some positive findings 
in comparison to previous ones [168, 169]. Not major AEs are reported (usually 
mouth ulcers and gastrointestinal complaints). CHS does not recommend the use of 
Feverfew for migraine prevention; AAN/AHS recommends it as probably effective 
(level B) and EFNS as possibly effective (level C).
3.5.6 Ginkgolide-B
Ginkgolide-B is an extract from Ginkgo biloba tree that has shown efficacy in the 
prevention of migraine in a small-size, open label study [170], without any other 
confirmation.
3.5.7 Omega-3 polyunsaturated fatty acids (OPFAs)
The exact mechanism of OPFAs in migraine is unknown. One placebo-con-
trolled study showed no significant difference between active and placebo group in 
reduction of migraine days [171].
3.6 Dietary interventions
Different types of dietary interventions have been suggested and studied in 
migraine prevention such as weight loss diet, low fat diets, ketogenic diets, and 
elimination diets, being the most popular and well-studied ones, and there are 
reports for several others. Because of the high comorbidity of headache with 
obesity, weight loss diet is a promising approach linked through inflammatory 
mediators that are released from adipose tissue. Nevertheless, it does not come out 
that weight loss or change in dietary intake may attenuate migraine frequency [172].
3.7 Acupuncture
Unrelated to placebo effect, a proportion of patients respond to acupuncture 
treatment in practice. From recently reviews, acupuncture shows at least not infe-
rior efficacy in the prevention of migraine comparing to conventional prophylactic 
treatment at a 3-month follow-up vs. placebo, although there is lot of discussion 
about the high proportion of placebo effect in this procedure (no significant differ-
ence between verum acupuncture vs. sham acupuncture groups) [173, 174]. Only 
minor gastrointestinal AEs are reported. Despite the debatable mechanism of action 
and the methodological shortcomings of the relative research, the evidence suggests 
its use in migraine prevention, representing a therapeutic option for those patients 
who do not prefer medicinal treatments or display nocebo behaviors, which are very 
prevalent among migraineurs [11]. High recurrence rates after 6-month follow-up 
have been reported, however [174].
3.8 Physical therapy
The use of physical activity in alleviating the burden of migraine is unclear and 
data are missing. A cross-sectional study showed that physically active respondents 
had lower odds of migraine than moderately active respondents [175]. Physical 
treatment may have an effect, however, several musculoskeletal dysfunctions, in 
particular neck pain and vestibular symptoms have been reported to coexist with 
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migraine [176, 177]. Thus, physical interventions may improve clinical outcomes 
when combined with pharmacotherapy. These include manual treatment of trig-
ger points and stretching of the sternocleidomastoid and upper trapezius muscles, 
among other techniques (e.g., relaxation and aerobic exercise). Although physical 
therapy is recommended [178], the evidence of efficacy is very limited, and the 
documentation is rather empirical. A meta-analysis of controlled trials found that 
physical therapy techniques reduced the duration of migraine attacks but had no 
effect on pain intensity and attack frequency [179]. Thus, further investigation is 
needed.
4. Cognitive behavioral therapies
Though it is generally believed that biofeedback, relaxation training, and CBT 
improve migraine treatment outcomes either alone, or more often, in combina-
tion with medications, the evidence is poor. In one randomized trial among young 
patients (10–17 years old) suffering from chronic migraine, the use of CBT (10 
sessions) plus amitriptyline resulted in greater reductions in days with headache 
and migraine-related disability compared with the use of headache education plus 
amitriptyline [180]. A recent meta-analysis found that 54% of individuals with 
migraine reported at least 50% reduction in migraine frequency after psychological 
therapy, vs. 24% of controls [181]. Because CBT differs substantially from tradi-
tional psychotherapy, it focuses on here and now and it is typically time limited; this 
therapeutic option may help practitioners in migraine management, in pediatric 
populations in particular [182].
5. Patient centricity and patient education
Migraine is a heterogeneous disease with a spectrum of clinical manifesta-
tions varying between individuals. The choice of therapy requires an individual 
approach, as each patient is unique. Severity and frequency of attacks, disability 
causing, other symptoms, time to peak, patient preferences, comorbidities, drug 
interactions, side effects, and prior therapies that failed should be all taken into 
consideration [2]. Before proposing any therapeutic approach, local availability 
and accessibility to medications should also be considered. Patient preferences and 
needs of each individual are essential to achieve treatment adherence and patient-
reported satisfaction. Fast-acting drugs are generally preferred from patients with 
migraine during acute attacks [183]. Effectiveness of drugs seems to be the most 
important issue regarding prophylactic treatment, followed by time to effect and 
adverse events [184]. Although patient centricity has been established in the last 
years, it is not yet a standard practice to include patients at all appropriate levels of 
decision-making processes that are related to their health and well-being. Patient 
education is also of great significance to ensure treatment adherence. This could 
be achieved by thoroughly explaining patients’ disorder, purpose, and means of 
management. Ineffective clinician-patient communication is a major reason for 
patient treatment nonadherence. Patients thus should be counseled in advance on 
the potential benefits of the proposed therapy as well as on the treatment-related 
adverse effects that may appear. In conclusion, clinicians should always individual-
ize their treatment strategy to the specific needs of each migraine sufferer, with 
multidisciplinary approaches, usually both pharmaceutical and non-pharmaceu-
tical. Patients should be encouraged to take an active role in their own therapy 
[21]. Due to the heterogeneity of migraine, developers of guidelines should engage 
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solution.
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